Skyrizi goes head-to-head with rival IL-23 blocker

Positive results from the Phase III SEQUENCE study show the benefit of AbbVie’s (NYSE: ABBV) blockbuster biologic Skyrizi (risankizumab) in Crohn's disease.

The study pits Skyrizi against Johnson & Johnson’s (NYSE: JNJ) Stelara (ustekinumab), for the treatment of moderately to severely active disease, after one or more anti-TNFs have failed.

Presented at the United European Gastroenterology (UEG) Week 2023, the results show the trial met both primary endpoints of non-inferiority for clinical remission at week 24.